HK1052348B - 製備卡麥角林結晶i型的方法 - Google Patents

製備卡麥角林結晶i型的方法 Download PDF

Info

Publication number
HK1052348B
HK1052348B HK03104554.7A HK03104554A HK1052348B HK 1052348 B HK1052348 B HK 1052348B HK 03104554 A HK03104554 A HK 03104554A HK 1052348 B HK1052348 B HK 1052348B
Authority
HK
Hong Kong
Prior art keywords
cabergoline
toluene
diethyl ether
ether mixture
process according
Prior art date
Application number
HK03104554.7A
Other languages
English (en)
Chinese (zh)
Other versions
HK1052348A1 (en
Inventor
A‧托马斯
A‧托馬斯
S‧马格尼斯
M‧安格里
S‧馬格尼斯
G‧雷米拉
G‧帕兰扎
G‧帕蘭扎
Original Assignee
法玛西雅意大利公司
法瑪西雅意大利公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9888433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1052348(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 法玛西雅意大利公司, 法瑪西雅意大利公司 filed Critical 法玛西雅意大利公司
Publication of HK1052348A1 publication Critical patent/HK1052348A1/xx
Publication of HK1052348B publication Critical patent/HK1052348B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK03104554.7A 2000-03-24 2001-03-19 製備卡麥角林結晶i型的方法 HK1052348B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0007308.0A GB0007308D0 (en) 2000-03-24 2000-03-24 Process for preparing crystalline form | of cabergoline
GB0007308.0 2000-03-24
PCT/EP2001/003099 WO2001070740A1 (en) 2000-03-24 2001-03-19 Process for preparing crystalline form i of cabergoline

Publications (2)

Publication Number Publication Date
HK1052348A1 HK1052348A1 (en) 2003-09-11
HK1052348B true HK1052348B (zh) 2005-09-16

Family

ID=9888433

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03104554.7A HK1052348B (zh) 2000-03-24 2001-03-19 製備卡麥角林結晶i型的方法

Country Status (31)

Country Link
US (2) US6727363B2 (enExample)
EP (1) EP1272489B1 (enExample)
JP (1) JP4184666B2 (enExample)
KR (1) KR100827558B1 (enExample)
CN (1) CN1188412C (enExample)
AR (1) AR032449A1 (enExample)
AT (1) ATE250601T1 (enExample)
AU (2) AU780747B2 (enExample)
BR (1) BR0109507A (enExample)
CA (1) CA2402836A1 (enExample)
CZ (1) CZ20023176A3 (enExample)
DE (1) DE60100858T2 (enExample)
DK (1) DK1272489T3 (enExample)
EA (1) EA005928B1 (enExample)
EE (1) EE05088B1 (enExample)
ES (1) ES2208602T3 (enExample)
GB (1) GB0007308D0 (enExample)
HK (1) HK1052348B (enExample)
HU (1) HUP0300591A3 (enExample)
IL (2) IL150985A0 (enExample)
MX (1) MXPA02009283A (enExample)
MY (1) MY134189A (enExample)
NO (1) NO20024321L (enExample)
NZ (1) NZ521316A (enExample)
PE (1) PE20011140A1 (enExample)
PL (1) PL358253A1 (enExample)
PT (1) PT1272489E (enExample)
SI (1) SI1272489T1 (enExample)
SK (1) SK13582002A3 (enExample)
WO (1) WO2001070740A1 (enExample)
ZA (1) ZA200206045B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007307D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
MXPA04008935A (es) * 2002-03-15 2004-11-26 Pharmacia Corp Procedimiento para la preparacion de la forma i cristalina de la cabergolina.
US20060281777A1 (en) * 2002-03-15 2006-12-14 Pfizer Inc. Process for preparing crystalline form I of cabergoline
IL155545A (en) 2003-04-21 2009-12-24 Finetech Pharmaceutical Ltd Solvate form of cabergoline
KR20060028761A (ko) * 2003-05-08 2006-04-03 아이박스 파마슈티컬스 에스.알.오. 다형의 카베르골린
GB0409785D0 (en) * 2004-04-30 2004-06-09 Resolution Chemicals Ltd Preparation of cabergoline
GB0505965D0 (en) 2005-03-23 2005-04-27 Resolution Chemicals Ltd Preparation of cabergoline
GB0515430D0 (en) * 2005-07-27 2005-08-31 Resolution Chemicals Ltd Preparation of cabergoline
US7339060B2 (en) 2005-03-23 2008-03-04 Resolution Chemicals, Ltd. Preparation of cabergoline
EP1925616A1 (en) * 2006-10-26 2008-05-28 LEK Pharmaceuticals D.D. Process for the preparation of crystal forms of cabergoline via stable solvates of cabergoline
EP1953157A1 (en) 2007-01-31 2008-08-06 LEK Pharmaceuticals D.D. New crystal form of cabergoline
EP2185169A2 (en) * 2007-08-29 2010-05-19 Max Zeller Söhne AG Use of vitex agnus castus extracts for preparing a medicament
EP4074552B1 (en) * 2021-04-16 2024-04-03 Thermo King LLC Electrical connection unit

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3019322A1 (de) 1980-05-21 1981-12-03 Merck Patent Gmbh, 6100 Darmstadt Psychopharmakon sowie verwendung von adenosinderivaten
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
GB2103603B (en) * 1981-08-11 1985-04-11 Erba Farmitalia Ergoline derivatives
GB9205439D0 (en) * 1992-03-12 1992-04-22 Erba Carlo Spa Process for the synthesis of ergoline derivatives
AU680539B2 (en) 1993-08-18 1997-07-31 Alcon Laboratories, Inc. Use of ergoline derivatives for the treatment of glaucoma
WO1999036095A1 (en) 1998-01-13 1999-07-22 Astrazeneca Uk Limited PHARMACEUTICAL COMPOSITIONS COMPRISING A COMPOUND HAVING DOPAMINE (D2) RECEPTOR AGONIST ACTIVITY AND A COMPOUND (B) HAVING β2-ADRENORECEPTOR AGONIST ACTIVITY
EP1066038B1 (en) 1998-03-27 2005-12-21 Pharmacia & Upjohn Company LLC Use of cabergoline in the treatment of restless legs syndrome
GB0007307D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007309D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline

Also Published As

Publication number Publication date
CZ20023176A3 (cs) 2003-02-12
CN1419554A (zh) 2003-05-21
NO20024321D0 (no) 2002-09-10
EP1272489B1 (en) 2003-09-24
ES2208602T3 (es) 2004-06-16
AU2005203071B2 (en) 2007-10-18
DK1272489T3 (da) 2003-12-15
WO2001070740A1 (en) 2001-09-27
KR20020081587A (ko) 2002-10-28
AU780747B2 (en) 2005-04-14
EA200201016A1 (ru) 2003-02-27
GB0007308D0 (en) 2000-05-17
JP2003528100A (ja) 2003-09-24
DE60100858D1 (de) 2003-10-30
CN1188412C (zh) 2005-02-09
ATE250601T1 (de) 2003-10-15
NZ521316A (en) 2004-05-28
PE20011140A1 (es) 2001-11-01
HUP0300591A2 (hu) 2003-07-28
US6727363B2 (en) 2004-04-27
IL150985A0 (en) 2003-02-12
BR0109507A (pt) 2002-12-10
CA2402836A1 (en) 2001-09-27
PT1272489E (pt) 2004-02-27
MY134189A (en) 2007-11-30
US20030149067A1 (en) 2003-08-07
EP1272489A1 (en) 2003-01-08
US20040092744A1 (en) 2004-05-13
JP4184666B2 (ja) 2008-11-19
HUP0300591A3 (en) 2009-01-28
DE60100858T2 (de) 2004-07-29
EE200200545A (et) 2004-04-15
EE05088B1 (et) 2008-10-15
SI1272489T1 (en) 2004-02-29
AU2005203071A1 (en) 2005-08-11
HK1052348A1 (en) 2003-09-11
SK13582002A3 (sk) 2003-04-01
MXPA02009283A (es) 2003-03-12
EA005928B1 (ru) 2005-08-25
AR032449A1 (es) 2003-11-12
US6953854B2 (en) 2005-10-11
KR100827558B1 (ko) 2008-05-07
AU6211001A (en) 2001-10-03
ZA200206045B (en) 2003-07-29
PL358253A1 (en) 2004-08-09
NO20024321L (no) 2002-09-10
IL150985A (en) 2007-03-08

Similar Documents

Publication Publication Date Title
HK1052348A1 (en) Process for preparing crystalline form i of cabergoline
WO2012123325A1 (en) NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
CN1221550C (zh) 卡麦角林的晶型ii
US6680327B2 (en) Crystalline form VII of cabergoline
US20060281777A1 (en) Process for preparing crystalline form I of cabergoline
US7531551B2 (en) Polymorphs of cabergoline

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100319